Abridge vs Nabla

Nabla has the randomized trial. In an NEJM AI study of 238 outpatient physicians at a California academic system, Nabla users cut time in note by 9.5% against usual care (p=.02), while the DAX arm did not reach significance. Nabla was used in only about 29.5% of visits, though. Abridge's evidence is survey and pre-post work, such as a JAMIA Open result where 73% of users reported less documentation outside clinical hours. Its edge is Epic history: first Epic Pal partner in August 2023, against a Nabla Epic Toolbox listing from October 2025 that rests on a third-party summary. Third parties estimate Abridge at $208 to $600 per clinician per month plus implementation. Nabla bills a monthly per-user fee in euros excluding VAT, and its help center cites a 30-day trial. A group that wants trial evidence and a per-user euro fee buys Nabla. An Epic health system buys Abridge on the longer record, and a five-physician practice with no procurement team cannot, because Abridge sells to enterprises only. Nabla loses for the buyer who needs a published price or a written BAA, since its pricing page is a contact form and BAA availability is unconfirmed.